Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company

Rhea-AI Summary

Health Catalyst (Nasdaq: HCAT) has closed the sale of its Vitalware business, conducted through Vitalware, LLC, to Med-Metrix, LLC for $147 million in cash, subject to customary adjustments. The transaction closed on July 31, 2026.

Health Catalyst used the net cash proceeds plus cash on hand to fully repay and terminate all obligations under its credit facility, eliminating about $19 million in annual GAAP interest expense based on the first half of 2026. According to Health Catalyst, the strengthened balance sheet will support focused investment in its healthcare intelligence strategy and AI-driven products, leveraging $2.8 billion in documented outcomes across more than 380 client improvement case studies to help health systems improve cost, clinical quality, and consumer performance.

Positive

• $147 million total cash consideration from Vitalware sale, subject to adjustments
• Credit facility fully repaid and terminated using proceeds plus cash on hand
• Elimination of approximately $19 million in annual GAAP interest expense
• Balance sheet strengthened, increasing financial flexibility for core strategy investment
• Strategic focus on AI-driven intelligence products leveraging $2.8 billion documented outcomes

Negative

• Divestiture removes Vitalware mid-revenue cycle solutions from Health Catalyst portfolio

Market Context

Current risk data classified HCAT's short positioning as low. Against that backdrop, the completed s...

Analysis

Current risk data classified HCAT's short positioning as low. Against that backdrop, the completed sale's balance-sheet benefit is a platform datapoint; core-product execution remained the key factor to assess.

Key Figures

Cash consideration: $147 million Documented outcomes: $2.8 billion Annual interest expense eliminated: approximately $19 million +3 more

6 metrics

Cash consideration $147 million Vitalware transaction

Documented outcomes $2.8 billion Health Catalyst proprietary outcomes data

Annual interest expense eliminated approximately $19 million GAAP basis, annualized from the first half of 2026

Company data history 18 years Proprietary healthcare improvement data and analytics

Improvement case studies more than 380 case studies Documented healthcare improvement outcomes

Transaction closing date July 31, 2026 Sale of Vitalware to Med-Metrix

Historical Context

5 past events · Latest: Jun 16 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 16	Investor conference	Neutral	-0.6%	Management participation in a healthcare-focused investor conference panel
Jun 04	Vitalware acquisition	Positive	+45.9%	Med-Metrix announced a definitive agreement to acquire Vitalware from Health Catalyst
Jun 04	Vitalware divestiture	Positive	+45.9%	Health Catalyst announced a $147 million cash divestiture to Med-Metrix
May 11	First-quarter earnings	Positive	+7.3%	Adjusted EBITDA increased while 2026 revenue and EBITDA guidance were provided
May 01	Earnings scheduling	Neutral	+16.0%	The company scheduled its first-quarter results release and conference call

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

HCAT's prior divestiture and earnings announcements aligned with positive reactions, while conference and scheduling notices diverged from their neutral classifications.

Key Terms

credit facility, gaap, revenue cycle management, chargemaster

4 terms

credit facility financial

"fully repay and terminate all of its obligations under its credit facility"

A credit facility is a flexible loan arrangement that allows a borrower to access funds up to a set limit whenever needed, similar to a company having an overdraft option on a bank account. It matters to investors because it indicates how easily a business can secure cash when required, affecting its ability to manage expenses, invest, or respond to financial challenges.

gaap financial

"eliminates approximately $19 million in annual interest expense on a GAAP basis"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

revenue cycle management financial

"a technology-enabled revenue cycle management company"

Revenue cycle management is the set of processes a healthcare provider or medical business uses to turn patient care into cash, including registering patients, billing insurers, submitting claims, collecting payments and handling denials. Think of it as the organization’s checkout system and follow-up team; efficient management shortens the time to get paid, reduces lost revenue and lowers financial risk, which directly affects cash flow and profitability that investors watch closely.

chargemaster technical

"coding compliance, chargemaster management, charge capture, and price transparency"

A chargemaster is a hospital or health system’s master list of billable items and the official prices assigned to procedures, services, supplies, and medications. Think of it as a retailer’s catalog of sticker prices before discounts: insurers, government programs, and patients rarely pay the full listed amounts, but the chargemaster sets the starting point for billing, reimbursement negotiations, reported gross charges and potential regulatory or transparency scrutiny—factors that can affect an organization's reported revenue and financial risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company retires all credit facility debt; transaction reflects concentrating its technology on improving health system performance.

SALT LAKE CITY, Aug. 6, 2026 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst" or the "Company," Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced it closed the sale of Vitalware, LLC, through which the Company conducted its Vitalware business, to Med-Metrix, LLC, a technology-enabled revenue cycle management company, on July 31, 2026. Having used the net cash proceeds plus cash on hand to fully repay and terminate all of its obligations under its credit facility, Health Catalyst plans to focus its capital and its people on its highest-conviction technology, designed for the pressures defining the health system agenda: managing cost, advancing clinical quality, and earning consumer loyalty, all at once.

The Company plans to focus its product roadmap on delivering intelligence products that combine a client's data with the Company's $2.8 billion in documented outcomes to identify what can drive improvement for that client, then help carry that change through the organization. Organizations don't change; people do, so the Company is investing deliberately in its intelligence products to bring each plan down to what an individual can do differently, which is what Health Catalyst believes makes improvement last.

The transaction included $147 million in total cash consideration for Health Catalyst, subject to customary adjustments. The Company used those proceeds plus cash on hand to fully repay and retire its obligations under its credit facility, which eliminates approximately $19 million in annual interest expense on a GAAP basis, based upon annualizing the first half of 2026. The Company believes this strengthened balance sheet will provide financial flexibility to invest decisively in its core strategy.

"We're excited about where we are headed," said Ben Albert, CEO of Health Catalyst. "To us, powerful analytics are essential, and our expertise is built on 18 years of what actually works. What comes next is the part that we believe matters most: pairing that with knowing where to act, in what order, and with what impact, and the support to help make change stick. That's the problem we're working to solve, and we believe we are well-positioned to solve it."

Health Catalyst is focusing on pairing 18 years of proprietary healthcare improvement data and analytics with AI-driven products and the human expertise to put it to work. With the divestiture behind it, Health Catalyst is investing in the intelligence layer—the proprietary data, benchmarks, and expertise that the Company believes set it apart—which is at the core of the products it's developing. These are designed to deepen the advantage that turns Health Catalyst's data into results. Data is the foundation. Intelligence is what the Company is building now, with its advantage of 18 years of proprietary healthcare improvement data: $2.8 billion in documented outcomes, across more than 380 client improvement case studies. 

About Vitalware
Vitalware, formerly by Health Catalyst, is a suite of mid-revenue solutions that help hospitals and health systems improve coding compliance, chargemaster management, charge capture, and price transparency across the mid-revenue cycle. It combines healthcare-specific data models, applied AI, and expert support to deliver measurable financial and operational results.

About Health Catalyst 
Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action.

Advisors

Raymond James served as the exclusive financial advisor, and Latham & Watkins LLP served as outside legal counsel for Health Catalyst.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding Health Catalyst's competitive advantages, Health Catalyst's ability to realize the expected impact and benefits from the divestiture of Vitalware (including increased financial flexibility and ability to invest in core products), Health Catalyst's ability to execute on its strategic transformation, strategic priorities (including its product roadmap), investment strategy, long-term strategy, and growth. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Important risks and uncertainties that could cause actual results to differ materially from Health Catalyst's expectations, plans and prospects, including the benefits that will be derived from this transaction, include without limitation, (i) changes in laws and regulations applicable to Health Catalyst's business model; (ii) changes in market or industry conditions, regulatory environment, and receptivity to Health Catalyst's technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key clients or partners, clients reducing or eliminating their spend with Health Catalyst, client churn or down-selling in connection with the migration to Ignite or otherwise; (v) fluctuations in Health Catalyst's project-based, non-recurring revenue, (vi) macroeconomic challenges (including high inflationary and/or high interest rate environments, tariffs, or market volatility and measures taken in response thereto), natural disasters or any new public health crises, and regional or global conflicts (including in the Middle East); (vii) the divestiture of Vitalware may not achieve some or all of the expected benefits and may adversely affect Health Catalyst's business; and (viii) changes to Health Catalyst's abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect Health Catalyst's actual results, please refer to the risk factors identified in Health Catalyst's SEC reports, including, but not limited to, the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, expected to be filed with the SEC on or about August 6, 2026, and the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026 and further amended on April 30, 2026. All information provided in this release is as of the date hereof, and Health Catalyst undertakes no duty to update or revise this information unless required by law.

Health Catalyst Investor Relations Contact
Stephanie St. Clair
Finance and Investor Relations, SVP
+1 (855)-309-6800
ir@healthcatalyst.com

Health Catalyst Media Contact
Kay Blazar
VP, PR
SVM PR & Marketing
Healthcatalyst@SVMPR.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/health-catalyst-completes-sale-of-vitalware-sharpening-its-focus-as-a-healthcare-intelligence-company-302845367.html

SOURCE Health Catalyst

FAQ

What did Health Catalyst (HCAT) announce about the sale of Vitalware on August 6, 2026?

Health Catalyst announced it completed the sale of Vitalware, LLC to Med-Metrix for $147 million in cash, subject to adjustments. According to Health Catalyst, the deal closed on July 31, 2026 and forms part of a strategy to sharpen its focus as a healthcare intelligence company.

How much cash did Health Catalyst (HCAT) receive from selling Vitalware and how was it used?

Health Catalyst received $147 million in total cash consideration from the Vitalware sale, subject to customary adjustments. According to Health Catalyst, it used these proceeds plus cash on hand to fully repay and retire all obligations under its credit facility, strengthening its balance sheet and reducing interest expense.

How does the Vitalware sale affect Health Catalyst’s (HCAT) debt and interest expense?

The Vitalware sale allowed Health Catalyst to fully repay and terminate its credit facility, removing that debt. According to Health Catalyst, this repayment eliminates approximately $19 million in annual interest expense on a GAAP basis, based on annualizing results from the first half of 2026.

What strategic focus did Health Catalyst (HCAT) outline after divesting Vitalware?

After divesting Vitalware, Health Catalyst plans to focus capital and people on its highest-conviction healthcare intelligence technology. According to Health Catalyst, it is prioritizing AI-driven intelligence products that combine client data with $2.8 billion in documented outcomes to drive measurable health system improvements.

How will the Vitalware divestiture impact Health Catalyst’s (HCAT) product roadmap?

Health Catalyst plans to center its product roadmap on intelligence products that guide where and how to act for improvement. According to Health Catalyst, these offerings will pair 18 years of proprietary healthcare improvement data with AI and human expertise to help organizations sustain change.

What is Vitalware and what did it provide before its sale by Health Catalyst (HCAT)?

Vitalware was a suite of mid-revenue cycle solutions focused on coding compliance, chargemaster management, charge capture, and price transparency. According to Health Catalyst, it combined healthcare-specific data models, applied AI, and expert support to deliver measurable financial and operational results for hospitals and health systems.

How much proprietary outcomes data does Health Catalyst (HCAT) leverage in its intelligence products?

Health Catalyst leverages $2.8 billion in documented outcomes across more than 380 client improvement case studies. According to Health Catalyst, this 18-year dataset underpins its healthcare intelligence products, which aim to turn health system data into confident, measurable action across cost, clinical, and consumer performance.